Halozyme To Report First Quarter 2023 Financial and Operating Results

Rhea-AI Summary

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced plans to release its first-quarter 2023 financial and operating results on May 9, 2023, after the trading day concludes. A conference call will follow at 4:30 p.m. ET to discuss the results, accessible via pre-registration.

The call will also be available as a live webcast on the company's website. Halozyme is focused on enhancing patient experiences through its innovative ENHANZE® technology, which improves the delivery of injected medications. As of now, it has impacted over 700,000 patients globally.

Halozyme partners with major pharmaceutical firms like Roche and Pfizer, and it has a range of commercial products, including XYOSTED®, TLANDO®, and NOCDURNA®.

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating results on Tuesday, May 9, 2023, following the close of trading.

Halozyme will host a conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET/1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration via this link: https://conferencingportals.com/event/QfiVLXsr

A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. As the innovators of the ENHANZE^® technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the delivery of injected drugs and fluids in order to reduce the treatment burden to patients. Having touched more than 700,000 patient lives in post-marketing use in five commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE^® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and Chugai Pharmaceutical.

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The Company has a commercial portfolio of proprietary products including XYOSTED^®, TLANDO^® and NOCDURNA^® and partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceutical, Pfizer and Idorsia Pharmaceuticals.

Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.

For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.

Contacts:

Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com

Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-first-quarter-2023-financial-and-operating-results-301806552.html

SOURCE Halozyme Therapeutics, Inc.

FAQ

When will Halozyme report its first-quarter 2023 financial results?

Halozyme will report its first-quarter 2023 financial results on May 9, 2023, after the market closes.

What time is the Halozyme conference call on May 9, 2023?

The Halozyme conference call is scheduled for 4:30 p.m. ET on May 9, 2023.

How can I listen to the Halozyme conference call?

You can listen to the Halozyme conference call live by pre-registering through their provided link.

What is Halozyme's ENHANZE® technology?

Halozyme's ENHANZE® technology is an innovative solution that improves the delivery of injected drugs, enhancing patient experience.

How many patients have benefited from Halozyme's products?

Halozyme's products have touched the lives of over 700,000 patients across more than 100 global markets.